

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CNSX Issuer: MARAPHARM VENTURES INC. (the "Issuer").

Trading Symbol: MDM

Number of Outstanding Listed Securities: 38,032,573

Date: February 3, 2016

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*The Issuer is a public Company established to invest in emerging markets in the medical and recreational marijuana industry. The business model is to apply for and purchase licenses and facilities in strategic locations. The Issuer intends to create a global entity by pursuing commercial venture in the medical marijuana*

*business. Pursuant to the share exchange agreement, the Issuer acquired all of the issued and outstanding shares of Marapharm Inc. Marapharm Inc. has a medical marihuana license department whose function is to research and obtain licenses and development permits for medical marihuana in 23 states in the U.S. where medical marihuana can be sold. Through Marapharm Inc., a wholly owned subsidiary, the Issuer has acquired Maragold, committed to providing other synergies and products for people to increase their overall quality of life. intends to re-brand and repackage the product line with the goal of marketing and selling them online.*

**During the month of January 2016, the Issuer announced the extension to the expiry date of 5,059,670 share purchase warrants, exercisable at a price of \$0.75 per share to January 19, 2016, for an additional year to January 19, 2017. The Issuer continues to pursue a Canadian medical marijuana licence.**

2. Provide a general overview and discussion of the activities of management.

**The Issuer continues to pursue a Canadian medical marijuana licence. The Issuer's wholly owned subsidiary, Marapharm Inc's application to Health Canada has progressed to the security clearance stage. There are several stages to the application process, but the security clearance stage is a significant milestone in the process. The Issuer's wholly owned subsidiary, Marapharm Las Vegas LLC, in advance of the planned 80,000 sq. ft. main cultivation facility, will commence construction of a 5,000 sq. ft. medical marijuana complex on the 5.9 acres it owns in the Apex Industrial Park, located north of Las Vegas, Nevada. The facility will provide interim product to local dispensaries. The building is ordered and will be used for hiring, training and cultivation during the construction of the main facility.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**There were no new products or services developed or offered in the month of January 2016.**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**No products or services were discontinued in the month of January 2016.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None during the month of January 2016.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None in the month of January 2016.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None in the month of January 2016.**

8. Describe the acquisition of new customers or loss of customers.

**There were no acquisition of new customers or loss of customers in the month of January 2016.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks in the month of January 2016.**

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

**The Issuer did not hire, terminate or lay off any employee during the month of January 2016.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None during the month of January 2016.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**There were no legal proceedings during the month of January 2016.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None during the month of January 2016.**

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
N/A			

*(1) State aggregate proceeds and intended allocation of proceeds.*

15. Provide details of any loans to or by Related Persons.

**None during the month of January 2016.**

16. Provide details of any changes in directors, officers or committee members.

**There were no other changes in directors, officers or committee members during the month of January 2016.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Issuer has no history of operations. Even if the medical marihuana licenses are issued to the Issuer by Health Canada and/or state regulatory agencies in the United States, there is no guarantee that the production facility will be constructed nor is there any guarantee that the business model of producing and selling marihuana will be a viable business. Significant funds are required to construct the facility, to obtain the license, and to market and sell medical marihuana to the public. Other companies are already either licensed to produce medical marihuana or are in a more advanced state in achieving their license.**

**The market for medical marihuana in Canada is tightly controlled. The Issuer's ability to grow, store and sell medical marijuana in Canada is dependent on the Issuer obtaining "licensed producer" status from Health Canada and the financial condition of the Issuer. There is potential that the Issuer will face intense competition from other companies, some of which can be expected to have longer operating histories and greater financial resources and manufacturing and marketing experience than the Issuer. Because of the early stage of the industry in which the Issuer intends to operate, the Issuer expects to face additional competition from new entrants.**

## **Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 3, 2016

Les Kjosness  
 Name of Director or Senior Officer  
 “  
 -  
Les Kjosness”  
 Signature  
President/CEO  
 Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer	For Month End	Date of Report YY/MM/DD
<b>MARAPHARM VENTURES INC.</b>	<b>Jan 2016</b>	<b>2016/02/03</b>
Issuer Address		
<b>Unit 12 – 7621 Vantage Way</b>		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
<b>Delta, BC V4G 1A6</b>	<b>(604)952-0988</b>	<b>(604) 952-6676</b>
Contact Name	Contact Position	Contact Telephone No.
<b>Les Kjosness</b>	<b>President</b>	<b>(604) 952-6676</b>
Contact Email Address	Web Site Address	
<b>Les.k@telus.net</b>	<b>www.marapharmventures.com</b>	